Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Optomed Oyj Board/Management Information 2021

Sep 13, 2021

3329_rns_2021-09-13_98cc0901-7666-475f-b68b-2872c711cad6.html

Board/Management Information

Open in viewer

Opens in your device viewer

Composition of Optomed’s Nomination Board

Composition of Optomed’s Nomination Board

Optomed Plc         Stock Exchange Release    13 September 2021 at 15:00,
Helsinki

Composition of Optomed’s Nomination Board

According to Optomed’s shareholder register of 1 September 2021, the
shareholders represented in the shareholders’ Nomination Board are OP
-Rahastoyhtiö Oy (OP funds), Aktia Rahastoyhtiö Oy (Aktia funds) and Finnish
Industry Investment Ltd. These shareholders have appointed the following persons
to the Nomination Board:

· Vesa Vanha-Honko, OP funds
· Markus Lindqvist, Aktia funds
· Keith Bonnici, Finnish Industry Investment Ltd

Petri Salonen, Chairman of Optomed’s Board of Directors, will serve as the
Nomination Board's expert member.
According to the resolution of Optomed General Meeting, the Optomed Nomination
Board consists of the representatives of Optomed three largest shareholders as
of the first trading day September, and the Chairman of the Board of Directors
as an expert member. Should a shareholder not wish to exercise the nomination
right, the right shall be transferred to the next largest shareholder who
otherwise would not be entitled to nominate a member.
The Nomination Board is to prepare proposals on the composition and members of
the Board of Directors and their remuneration for the next Annual General
Meeting and it will submit its proposal to the Board of Directors 31 January
2022 at the latest.

Optomed Plc

Further enquiries

Petri Salonen, Chairman of the Board, Optomed Plc, [email protected]

Sakari Knuutti, CLO, Optomed Plc, [email protected]

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld cameras with software and
artificial intelligence with the aim to transform the diagnostic process of
blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its
business Optomed focuses on eye-screening devices and software solutions related
R&D in Finland and sales through different channels in over 60 countries.